Semaglutide and Tirzepatide Compounding Shortage Resolution

The story of Semaglutide and Tirzepatide compounding is one of the most significant regulatory events in modern pharmacy compounding. When these blockbuster GLP-1 receptor agonist drugs experienced shortages, compounding pharmacies stepped in to fill the gap — creating a multi-billion dollar market that the FDA then moved to shut down once shortages resolved.

Background: The GLP-1 Shortage

Semaglutide (Ozempic / Wegovy)

Semaglutide, manufactured by Novo Nordisk and sold as Ozempic (diabetes) and Wegovy (weight loss), experienced severe shortages beginning in 2022:

• Cause: Explosive demand driven by weight loss applications far exceeding manufacturing capacity
• FDA shortage listing: Semaglutide was placed on the FDA Drug Shortage List
• Compounding opportunity: Under Section 503A and 503B of the FD&C Act, pharmacies can compound copies of drugs that are on the shortage list
• Market size: Compounded semaglutide became a multi-billion dollar market, with prices often 80-90% lower than branded versions

Tirzepatide (Mounjaro / Zepbound)

Tirzepatide, manufactured by Eli Lilly and sold as Mounjaro (diabetes) and Zepbound (weight loss), faced similar dynamics:

• Shortage listing: Also placed on the FDA Drug Shortage List
• Compounding: Pharmacies began compounding tirzepatide as well
• Competition: Eli Lilly aggressively fought compounding through legal and regulatory channels

Timeline of Key Events

The Shortage Resolution

Semaglutide (October 2024)

On October 2, 2024, the FDA officially removed semaglutide injection from the Drug Shortage List, determining that Novo Nordisk had resolved supply issues. This triggered significant consequences:

Immediate effects:

• Compounding pharmacies were required to cease semaglutide compounding within a wind-down period
• Patients on compounded semaglutide faced abrupt price increases switching to branded versions
• Telehealth platforms built around compounded semaglutide faced existential business challenges

Legal response:

• The Outsourcing Facilities Association (OFA) and multiple compounding pharmacies filed lawsuits
• Key argument: FDA’s determination was premature; shortages persisted in many regions
• Some federal courts granted temporary restraining orders allowing continued compounding
• The legal landscape remained unsettled through early 2026

Tirzepatide (Fluctuating Status)

Tirzepatide’s shortage status was more volatile:

• Eli Lilly increased manufacturing capacity but demand continued to outpace supply for certain dosage strengths
• The drug was removed from and re-added to the shortage list multiple times
• As of early 2026, the status continued to fluctuate, creating uncertainty for compounders
• Eli Lilly took a more aggressive legal stance than Novo Nordisk, suing individual compounding pharmacies

Implications for 503A and 503B Compounders

503A Pharmacies (Traditional Compounding)

• Can only compound a commercially available drug when it is on the FDA shortage list
• Once the drug comes off the shortage list, compounding must stop (subject to wind-down period)
• Patient-specific prescriptions required
• Many small 503A pharmacies had invested in semaglutide compounding infrastructure that became stranded

503B Outsourcing Facilities

• Can compound larger batches without patient-specific prescriptions
• Same shortage list limitations apply
• Several 503B facilities had scaled up specifically for GLP-1 compounding
• The revenue impact of losing semaglutide was significant — some facilities derived 50%+ of revenue from GLP-1 compounding

Broader Implications

Precedent for Future Shortages

• The semaglutide saga establishes how aggressively the FDA will act to protect branded drug markets once shortages resolve
• Compounders now face the risk that any shortage-based compounding opportunity can be shut down abruptly
• Legal precedent from the ongoing cases will shape future compounding rights

Connection to Peptide Regulation

• The semaglutide compounding fight is related to but distinct from the peptide Category 2 designations
• Semaglutide is an FDA-approved drug; the peptides on Category 2 have never been approved
• However, the regulatory posture of the FDA toward compounding in general affects both areas
• The Kennedy reclassification of peptides may also affect the GLP-1 compounding landscape

Price and Access

• Compounded semaglutide: ~$100-300/month
• Branded Wegovy: ~$1,300/month
• The price differential made compounding enormously popular and created powerful economic incentives on both sides
• Patient access remains the central policy tension

Related Notes

• FDA-503A-Category-System — the regulatory framework for compounding
• FDA-Category-2-Designations-2023-2024 — related peptide compounding restrictions
• FDA-Reclassification-Announcement-Feb-2026 — broader regulatory shifts under Kennedy